AllPennyStocks.com Capricor Draws Investor Attention As Shareholder Kaos Capital Pushes For Board Shakeup Ahead Of Key FDA Decision On DMD Therapy
This section contains press releases and other materials from third parties (including paid content). AllPennyStocks.com has not reviewed this content. Please see our disclaimer.

Capricor Draws Investor Attention As Shareholder Kaos Capital Pushes For Board Shakeup Ahead Of Key FDA Decision On DMD Therapy

In a letter to Capricor’s shareholders, Kaos said it intends to nominate two independent directors and to have the company establish a board-led M&A and Strategic Alternatives Committee.

Other Penny Stock Movers

65,000 Patients a Year, Zero Approved Drugs, One Phase 3 Trial
$4.5 Million Could Unlock a Major Cannabis Market
Chilean Gold Developer Gains 15% on Final Permit Clearance
Most Popular
{{ index + 1 }}


Back to Top